Logo

Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021

Share this
Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung Cancer at ESMO 2021

Shots:

  • The P-III study evaluates the efficacy- safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs reference Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV nonsq. NSCLC across Russia- Belarus- Ukraine & India
  • The study showed an equivalent efficacy- ORR (34.6% & 33.8%)- 341 patients had 1 CT scan after initiation of treatment- patients achieved stable disease (31.7% & 33.8%); CR (1.5% & 0.7%); PR (33.2% & 33.1%) @18wks. & continue with BCD-021 until disease progression- death- or unacceptable toxicity
  • Patients experienced AEs (91.3% vs 93.4%); serious AEs (13.6% vs 10.9%)- treatment discontinuation due to AEs- treatment-related serious AEs (3.4% vs 2.2%)- respectively

  | Ref: Biocad | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions